MicroPET imaging of MCF-7 tumors in mice via unr mRNA-targeted peptide nucleic acids.
As more becomes known about the expression profiles of normal and cancerous cells, it should become possible to design antisense-based imaging agents for the early detection of cancer noninvasively. In this report, we rationally designed and synthesized three antisense and one sense hybrid PNA (peptide nucleic acid) to the unr mRNA that is highly overexpressed in a breast cancer cell line (MCF-7). The conjugates had a four-lysine tail at the carboxy terminus for cell permeation and a DOTA (1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid) chelating moiety at the amino terminal end for chelating (64)Cu for biodistribution and microPET imaging studies. Biodistribution of two (64)Cu-labeled conjugates with antisense and sense sequences (PNA50 and PNA50S) showed high uptake and long retention in kidney and low uptake and efficient clearance in blood and muscle in normal balb/c mice when administered intravenously or intraperitoneally. Intraperitoneal administration, however, gave a much slower release rate. MCF-7 tumors (100-320 mg) in CB-17 SCID mice were imaged with all four (64)Cu-labeled PNA conjugates by microPET, but the image contrast varied with different time points and different conjugates. Of the conjugates studied, (64)Cu-DOTA-Y-PNA50-K4 showed the best tumor image quality at all time points with a tumor/muscle ratio of 6.6 +/- 1.1 at 24 h postinjection, which is among the highest reported for radiolabeled oligonucleotides. Our work further strengthens the potential of antigene and antisense PNAs to be utilized as specific molecular probes for early detection of cancer and ultimately for patient specific radiotherapy.
Sun
Xiankai
X
Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Fang
Huafeng
H
Li
Xiaoxu
X
Rossin
Raffaella
R
Welch
Michael J
MJ
Taylor
John-Stephen
JS
D000818:Animals; D045744:Cell Line, Tumor; D002463:Cell Membrane Permeability; D003301:Copper Radioisotopes / Q000493:pharmacokinetics; D006573:Heterocyclic Compounds, 1-Ring / Q000493:pharmacokinetics; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D016513:Mice, SCID; D009374:Neoplasms, Experimental / Q000175:diagnosis*; D016376:Oligonucleotides, Antisense / Q000493:pharmacokinetics; D020135:Peptide Nucleic Acids / Q000493:pharmacokinetics; D012334:RNA, Neoplasm / Q000378:metabolism*; D014018:Tissue Distribution
D003301:Copper Radioisotopes; D006573:Heterocyclic Compounds, 1-Ring; D016376:Oligonucleotides, Antisense; D020135:Peptide Nucleic Acids; D012334:RNA, Neoplasm; C071349:1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid